Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Nov 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-11-03

Reporting Person: Hack Andrew A. F. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-03	Common Stock	C	5365659	—	Acquired	5365659	Indirect
2020-11-03	Common Stock	P	250000	$24.00	Acquired	5615659	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-03	Series D Convertible Preferred Stock	$	C	3383190	Disposed		Common Stock (3383190)	Indirect
2020-11-03	Series D-1 Convertible Preferred Stock	$	C	1982469	Disposed		Common Stock (1982469)	Indirect

Footnotes

F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F4: On November 3, 2020, BCLS II Investco purchased 250,000 shares of common stock of the Issuer at a price of $24.00 per share, pursuant to an underwritten public offering.